Recombinant Proteins Market by Product (Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins), Services (Cloning, Expression, Purification), End-User, Function - Global Forecast 2024-2030
The Recombinant Proteins Market size was estimated at USD 5.05 billion in 2023 and expected to reach USD 5.80 billion in 2024, at a CAGR 14.51% to reach USD 13.04 billion by 2030.
The recombinant proteins are created by inserting a modified gene into an expression system such as bacteria, yeast, or mammalian cells, which then produce the desired protein with high purity and functionality. Recombinant proteins involve research, development, manufacturing, and commercialization of genetically engineered proteins derived from recombinant DNA technology. The prevalence of infectious and chronic diseases, increasing healthcare expenditure needed for new therapeutics and diagnostics, and increased R&D investments within biopharmaceutical companies are raising the need for high-quality recombinant proteins. The rapid advancements in genomics technologies and growing adoption of biologics over small-molecule drugs are resulting in increased adoption of recombinant proteins. However, the high cost of production and maintenance may adversely impact the use of recombinant DNA by the end-use industries. In addition, the emerging applications in animal reproduction and to enhance feed efficiency and significant investments in recombinant protein development are the factors expected to encourage the use of these proteins by the end-use sectors worldwide.
Regional Insights
The recombinant protein market is evolving in the Americas owing to the presence of well-established pharmaceutical and biotech companies with advanced research facilities and regulations that ensure high-quality products. Additionally, technological advancements, significant increases in funding for research and development (R&D), the rising prevalence of chronic conditions, and a surge in demand for personalized medicines are resulting in an increased need for recombinant protein in the Americas. The EMEA region represents a developing landscape for the recombinant proteins market owing to the stringent regulations implemented to use these proteins and the requirement for manufacturers to adhere to GMP standards. The recombinant proteins market is growing in the APAC region due to the prevalence of chronic diseases, increased research activities in cell biology, biochemistry, structural and biophysical studies, and the need for efficient biopharmaceuticals. Moreover, technological advancements and collaborations between biopharmaceutical companies and academic institutions are expected to increase the translation of laboratory innovations into commercially viable products and boost the adoption of recombinant proteins by the end-use sectors across the globe.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Recombinant Proteins Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Rising focus on personalized medicine & protein therapeutics in the consumers
- High prevalence of infectious & chronic diseases among geriatric population and children
- Surging inclination of demand toward biologics and biosimilars proteins
- Market Restraints
- Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
- Market Opportunities
- Increasing focus on biomarker discovery and surging investments recombinant protein development
- Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
- Market Challenges
- Availability of alternative products and several issues in production
- Market Segmentation Analysis
- Product: Significant use of adhesion molecules & receptors for research purposes
- Services: Expression services focus on high yields and compatibility with target protein characteristics
- End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
- Function: Potential demand of recombinant proteins for drug discovery & development
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Recombinant Proteins Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Recombinant Proteins Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
U.S.-based iTolerance and Northway Biotech have agreed to manufacture Streptavidin-FasL (SA-FasL) fusion protein, a critical component of iTolerance's proprietary iTOL-100 platform technology. This collaboration is aimed to provide treatment options that have the potential to cure diseases without the need for chronic immunosuppression.
Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
Biovian has invested EUR 50M in expanding its manufacturing facility in Turku, Finland, to offer end-to-end services, from development to commercial-scale production, for biopharmaceuticals. The new facility spans 6,400 m2 (69,000 ft2) and has advanced technologies and equipment to cater to Advanced Therapy Medicinal Products (ATMPs), including adenoviral and AAV therapies.
Fortis Life Sciences acquires International Point of Care
Fortis Life Sciences, LLC acquired International Point of Care, Inc.(IPOC) to provide customers with a comprehensive end-to-end solution for their immunodiagnostic and molecular diagnostic products. With this acquisition, Fortis can offer their customers top-quality materials and services that support advancements in ultra-high-sensitivity point-of-care diagnostics, multiplexing applications, quantitative lateral flow, isothermal amplification, and CRISPR-based diagnostics.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Recombinant Proteins Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bhat Bio-tech India Private Limited, Bio-Rad Laboratories, Inc., Biogen Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corp, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., Fortis Life Sciences LLC, GenScript Biotech Corporation, GeoVax Labs, Inc., Hzymes Biotech, Johnson & Johnson Services, Inc., Laurus Labs Limited, LenioBio GmbH, Lonza Group AG, Marin Biologic Laboratories, Inc., Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., Proteintech Group, Inc., Proteos, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Sanofi S.A., Sartorius AG, Selvita S.A., Sino Biological, Inc., SK bioscience, Takara Bio Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..
Market Segmentation & Coverage
This research report categorizes the Recombinant Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:- Product
- Adhesion Molecules & Receptors
- Growth Factors & Chemokines
- Immune Response Proteins
- Kinase Proteins
- Membrane Proteins
- Recombinant Metabolic Enzymes
- Regulatory Proteins
- Structural Proteins
- Services
- Cloning
- Expression
- Purification
- End-User
- Academic Research Institutes
- Contract Research Organizations & Contract Manufacturing Organizations
- Pharmaceutical & Biopharmaceutical Companies
- Function
- Diagnostics
- Drug Discovery & Development
- Biologics
- Cell & Gene Therapy
- Vaccines
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising focus on personalized medicine & protein therapeutics in the consumers
- 5.1.1.2. High prevalence of infectious & chronic diseases among geriatric population and children
- 5.1.1.3. Surging inclination of demand toward biologics and biosimilars proteins
- 5.1.2. Restraints
- 5.1.2.1. Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
- 5.1.3. Opportunities
- 5.1.3.1. Increasing focus on biomarker discovery and surging investments recombinant protein development
- 5.1.3.2. Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
- 5.1.4. Challenges
- 5.1.4.1. Availability of alternative products and several issues in production
- 5.2. Market Segmentation Analysis
- 5.2.1. Product: Significant use of adhesion molecules & receptors for research purposes
- 5.2.2. Services: Expression services focus on high yields and compatibility with target protein characteristics
- 5.2.3. End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
- 5.2.4. Function: Potential demand of recombinant proteins for drug discovery & development
- 5.3. Market Trend Analysis
- 5.3.1. Increase in research spending coupled with healthcare infrastructure across Americas
- 5.3.2. Prevalence of chronic diseases and significant investments in medical research in the APAC region
- 5.3.3. Expanding drug manufacturing facilities and regulatory guidelines for recombinant protein in the EMEA region.
- 5.4. Cumulative Impact of Russia-Ukraine Conflict
- 5.5. Cumulative Impact of High Inflation
- 5.6. Porter’s Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
- 5.7. Value Chain & Critical Path Analysis
- 5.8. Regulatory Framework Analysis
- 6. Recombinant Proteins Market, by Product
- 6.1. Introduction
- 6.2. Adhesion Molecules & Receptors
- 6.3. Growth Factors & Chemokines
- 6.4. Immune Response Proteins
- 6.5. Kinase Proteins
- 6.6. Membrane Proteins
- 6.7. Recombinant Metabolic Enzymes
- 6.8. Regulatory Proteins
- 6.9. Structural Proteins
- 7. Recombinant Proteins Market, by Services
- 7.1. Introduction
- 7.2. Cloning
- 7.3. Expression
- 7.4. Purification
- 8. Recombinant Proteins Market, by End-User
- 8.1. Introduction
- 8.2. Academic Research Institutes
- 8.3. Contract Research Organizations & Contract Manufacturing Organizations
- 8.4. Pharmaceutical & Biopharmaceutical Companies
- 9. Recombinant Proteins Market, by Function
- 9.1. Introduction
- 9.2. Diagnostics
- 9.3. Drug Discovery & Development
- 10. Americas Recombinant Proteins Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Recombinant Proteins Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Recombinant Proteins Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
- 13.3.2. Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
- 13.3.3. Fortis Life Sciences acquires International Point of Care
- 13.3.4. Curia Expands Cell Line Development Offering with CHOZN Platform
- 13.3.5. Future Fields raises USD 11.2 million to scale up fruit flies for recombinant protein production
- 13.3.6. Merck’s Biodevelopment Centre Expansion, Martillac, France
- 13.3.7. Shenandoah Biotechnology Introduces Expanded Range of CTGrade Recombinant Proteins Manufactured Following cGMP Practices
- 13.3.8. Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
- 13.3.9. Thermo Fisher Scientific Completes Acquisition of PeproTech, engaged in Recombinant Proteins
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook